CRL · Charles River Labs

S&P 500 #480 · NYSE

Risiko 6/10 · CRO Cyclical Recovery · $240.43 ▲ 7.19%

Kennzahlen

• Price $240.43
• Market cap $11.6B
• P/E (ttm) n/a
• Div yield none
• 52-wk range $144.26 – $242.73
• Index rank #480 / —

Wichtigste Risiken

• Negative EPS; profitability recovery uncertain (Earnings) — HIGH
• Biotech/pharma R&D spending cuts (Revenue) — HIGH
• China operations regulatory risk (Revenue) — HIGH
• Customer concentration in biopharma (Revenue stability) — MED

Fazit

Contract research org providing drug discovery/safety testing to pharma; recovering strongly but negative EPS reflects prior restructuring charges.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.